Trade Moderna Inc - MRNA CFD

Add to favourite

100.96

0.34%

0.36

Low: 100.27

High: 103.05

Market Trading Hours* (UTC) Opens on Monday at 08:10

Mon - Thu: 08:10 - 00:00

Fri: 08:10 - 21:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.36

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Moderna Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	101.3
Open*	101.75
1-Year Change*	-28.11%
Day's Range*	100.27 - 103.05
52 wk Range	62.55-198.86
Average Volume (10 days)	5.29M
Average Volume (3 months)	106.64M
Market Cap	37.77B
P/E Ratio	-100.00K
Shares Outstanding	381.28M
Revenue	9.12B
EPS	-9.36
Dividend (Yield %)	N/A
Beta	1.69
Next Earnings Date	Feb 22, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	101.00	-2.37	-2.29%	103.37	103.64	99.85
Apr 17, 2024	103.05	0.16	0.16%	102.89	105.47	102.20
Apr 16, 2024	103.45	0.50	0.49%	102.95	106.33	101.34
Apr 15, 2024	103.39	-1.06	-1.01%	104.45	106.11	102.20
Apr 12, 2024	104.86	-1.84	-1.72%	106.70	107.76	104.46
Apr 11, 2024	106.10	-0.59	-0.55%	106.69	108.37	103.64
Apr 10, 2024	106.90	-4.71	-4.22%	111.61	112.53	105.85
Apr 9, 2024	111.95	7.72	7.41%	104.23	115.80	103.95
Apr 8, 2024	104.65	2.20	2.15%	102.45	105.16	100.96
Apr 5, 2024	102.52	0.77	0.76%	101.75	103.73	101.01
Apr 4, 2024	101.55	0.28	0.28%	101.27	105.91	100.96
Apr 3, 2024	100.96	-2.69	-2.60%	103.65	104.95	96.95
Apr 2, 2024	103.41	-2.27	-2.15%	105.68	106.40	102.96
Apr 1, 2024	105.00	-1.97	-1.84%	106.97	108.37	103.50
Mar 28, 2024	106.57	-3.48	-3.16%	110.05	111.82	105.95
Mar 27, 2024	109.97	2.26	2.10%	107.71	112.93	104.97
Mar 26, 2024	107.36	-2.99	-2.71%	110.35	111.86	106.88
Mar 25, 2024	110.20	4.80	4.55%	105.40	110.79	105.08
Mar 22, 2024	105.15	0.86	0.82%	104.29	105.91	103.28
Mar 21, 2024	104.04	1.09	1.06%	102.95	106.26	102.50

Moderna Inc Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 12:00	Country US	Event Moderna Inc Annual Shareholders Meeting Moderna Inc Annual Shareholders Meeting Forecast - Previous -
Time (UTC) 12:30	Country US	Event Q1 2024 Moderna Inc Earnings Release Q1 2024 Moderna Inc Earnings Release Forecast - Previous -
Monday, May 6, 2024
Time (UTC) 12:00	Country US	Event Moderna Inc Annual Shareholders Meeting Moderna Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 1, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Moderna Inc Earnings Release Q2 2024 Moderna Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	19263	18471	803.395	60.209	135.068
Revenue	19263	18471	803.395	60.209	135.068
Total Operating Expense	9843	5175	1566.54	605.929	548.334
Selling/General/Admin. Expenses, Total	1132	567	188.267	109.62	94.252
Research & Development	3295	1991	1370.34	496.309	454.082
Operating Income	9420	13296	-763.144	-545.72	-413.266
Interest Income (Expense), Net Non-Operating	151	1	16.125	32.241	23.958
Net Income Before Taxes	9575	13285	-744.513	-514.716	-384.408
Net Income After Taxes	8362	12202	-747.064	-514.021	-384.734
Net Income Before Extra. Items	8362	12202	-747.064	-514.021	-384.734
Net Income	8362	12202	-747.064	-514.021	-384.734
Total Adjustments to Net Income			0	0	-17.123
Income Available to Common Excl. Extra. Items	8362	12202	-747.064	-514.021	-401.857
Income Available to Common Incl. Extra. Items	8362	12202	-747.064	-514.021	-401.857
Diluted Net Income	8362	12202	-747.064	-514.021	-401.857
Diluted Weighted Average Shares	416	431	381.333	330.802	328.799
Diluted EPS Excluding Extraordinary Items	20.101	28.3109	-1.95909	-1.55386	-1.2222
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS	20.101	28.3109	-1.95909	-1.55386	-1.2222
Other, Net	4	-12	2.506	-1.237	4.9
Cost of Revenue, Total	5416	2617	7.933
Gross Profit	13847	15854	795.462

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	344	1862	5084	3364	4749
Revenue	344	1862	5084	3364	4749
Cost of Revenue, Total	731	792	1918	1100	1381
Gross Profit	-387	1070	3166	2264	3368
Total Operating Expense	2211	2228	3504	2198	2302
Selling/General/Admin. Expenses, Total	332	305	375	278	211
Research & Development	1148	1131	1211	820	710
Operating Income	-1867	-366	1580	1166	2447
Interest Income (Expense), Net Non-Operating	113	65	75	46	27
Other, Net	5	-4	0	5	0
Net Income Before Taxes	-1749	-305	1655	1217	2474
Net Income After Taxes	-1380	79	1465	1043	2197
Net Income Before Extra. Items	-1380	79	1465	1043	2197
Net Income	-1380	79	1465	1043	2197
Income Available to Common Excl. Extra. Items	-1380	79	1465	1043	2197
Income Available to Common Incl. Extra. Items	-1380	79	1465	1043	2197
Diluted Net Income	-1380	79	1465	1043	2197
Diluted Weighted Average Shares	381	405	407	412	419
Diluted EPS Excluding Extraordinary Items	-3.62205	0.19506	3.59951	2.53155	5.24344
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-3.62205	0.19506	3.59951	2.53155	5.24344

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	13431	16071	6297.88	1128.8	1563.01
Cash and Short Term Investments	9902	10727	4607.61	1103	1521.43
Cash & Equivalents	3205	6848	2623.85	235.876	658.364
Short Term Investments	6697	3879	1983.76	867.124	863.063
Total Receivables, Net	1664	3296	1410.53	16.297	30.583
Accounts Receivable - Trade, Net	1385	3175	1390.56	5.369	12.585
Prepaid Expenses	851	531	232.185	8.475	10.401
Other Current Assets, Total	65	76	1.032	1.032	0.595
Total Assets	25858	24669	7336.75	1589.42	1962.15
Property/Plant/Equipment, Total - Net	2139	1383	387.09	287.909	211.977
Property/Plant/Equipment, Total - Gross	2797	1735	506.751	382.493	276.433
Accumulated Depreciation, Total	-658	-352	-119.661	-94.584	-64.456
Long Term Investments	8318	6843	638.848	159.987	172.99
Other Long Term Assets, Total	1970	372	12.933	12.722	14.176
Total Current Liabilities	4923	9128	4388.81	143.115	222.803
Accounts Payable	487	302	18.359	7.09	31.21
Accrued Expenses	2136	1518	475.563	71.236	79.073
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	2139	7143	3870.56	64.789	112.52
Total Liabilities	6735	10524	4775.38	414.612	431.908
Total Long Term Debt	912	599	109.874	38.689	33.489
Capital Lease Obligations	912	599	109.874	38.689	33.489
Other Liabilities, Total	900	797	276.693	232.808	175.616
Total Equity	19123	14145	2561.38	1174.81	1530.24
Preferred Stock - Non Redeemable, Net
Common Stock	0.0385	0	0.04	0.034	0.033
Additional Paid-In Capital	1173	4211	4801.85	2669.43	2538.16
Retained Earnings (Accumulated Deficit)	18320	9958	-2243.52	-1496.45	-1006.63
Other Equity, Total	-8.0385	-24
Total Liabilities & Shareholders’ Equity	25858	24669	7336.75	1589.42	1962.15
Total Common Shares Outstanding	385	403	398.788	336.537	328.799
Redeemable Preferred Stock	0	0	0	0	0
Unrealized Gain (Loss)	-362		3.004	1.804	-1.32
Total Inventory	949	1441	46.527
Current Port. of LT Debt/Capital Leases	161	165	24.328

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	10799	10599	12122	13431	14297
Cash and Short Term Investments	7573	8459	8923	9902	8348
Cash & Equivalents	2932	3801	3441	3205	3027
Short Term Investments	4641	4658	5482	6697	5321
Total Receivables, Net	2146	688	1521	1628	2821
Accounts Receivable - Trade, Net	1866	232	1113	1385	2695
Total Inventory	487	715	732	949	2077
Prepaid Expenses	497	684	882	887	889
Total Assets	19450	21884	24125	25858	26056
Property/Plant/Equipment, Total - Net	2717	2410	2135	2139	2132
Property/Plant/Equipment, Total - Gross	3789	3236	2871	2797	2712
Accumulated Depreciation, Total	-1072	-826	-736	-658	-580
Long Term Investments	5359	6224	7525	8318	8655
Other Long Term Assets, Total	478	2553	2243	1970	972
Total Current Liabilities	4385	3123	3499	4923	6807
Accounts Payable	494	310	389	487	330
Accrued Expenses	2257	1524	1641	2136	1892
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	150	187	153	161	224
Other Current Liabilities, Total	1484	1102	1316	2139	4361
Total Liabilities	5995	4935	5262	6735	8064
Total Long Term Debt	575	843	831	912	922
Capital Lease Obligations	575	843	831	912	922
Other Liabilities, Total	1035	969	932	900	335
Total Equity	13455	16949	18863	19123	17992
Redeemable Preferred Stock		0	0	0	0
Common Stock	0.0381	0.0381	0.0384	0.0385	0.0387
Additional Paid-In Capital	277	193	731	1173	1488
Retained Earnings (Accumulated Deficit)	13389	17019	18399	18320	16855
Unrealized Gain (Loss)	-211	-263	-362	-362	-406
Other Equity, Total	-0.0381	-0.0381	94.9616	-8.0385	54.9613
Total Liabilities & Shareholders’ Equity	19450	21884	24125	25858	26056
Total Common Shares Outstanding	381	381	384	385	387
Other Current Assets, Total	96	53	64	65	162
Goodwill, Net	52	52	52
Intangibles, Net	45	46	48

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	8362	12202	-747.064	-514.021	-384.734
Cash From Operating Activities	4981	13620	2026.97	-458.968	-330.865
Cash From Operating Activities	348	232	31.251	31.021	24.862
Deferred Taxes	-559	-318
Non-Cash Items	285	196	165.73	77.696	71.59
Cash Taxes Paid	2729	480	0.572	0.416	0.294
Changes in Working Capital	-3455	1308	2577.05	-53.664	-42.583
Cash From Investing Activities	-5176	-8523	-1671.93	-14.945	-373.094
Capital Expenditures	-400	-284	-67.448	-31.554	-105.766
Other Investing Cash Flow Items, Total	-4776	-8239	-1604.48	16.609	-267.328
Cash From Financing Activities	-3448	-873	2033.19	51.121	1226.84
Financing Cash Flow Items			0	0.971	11.635
Issuance (Retirement) of Stock, Net	-3264	-733	2039.41	50.15	1217.38
Issuance (Retirement) of Debt, Net	-184	-140	-6.215	0	-2.175
Net Change in Cash	-3643	4224	2388.24	-422.792	522.883
Cash Interest Paid	25	14	8.528

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	79	8362	6897	5854	3657
Cash From Operating Activities	-1225	4981	3319	3067	2763
Cash From Operating Activities	78	348	268	155	79
Deferred Taxes	-310	-559	-473	-376	-146
Non-Cash Items	80	285	235	138	62
Changes in Working Capital	-1152	-3455	-3608	-2704	-889
Cash From Investing Activities	2011	-5176	-4128	-5073	-3921
Capital Expenditures	-113	-400	-308	-219	-132
Other Investing Cash Flow Items, Total	2124	-4776	-3820	-4854	-3789
Cash From Financing Activities	-542	-3448	-3010	-1969	-642
Issuance (Retirement) of Stock, Net	-517	-3264	-2887	-1892	-611
Issuance (Retirement) of Debt, Net	-25	-184	-123	-77	-31
Net Change in Cash	244	-3643	-3819	-3975	-1800

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Moderna, Inc. Company profile

Get all the information you need on the Moderna stock price today with Capital.com’s comprehensive chart.

Moderna (MRNA) is a North American clinical-stage biotechnology company. Headquartered in Cambridge, Massachusetts, it specialises in drug discovery and development, as well as vaccine technologies based on messenger RNA (mRNA). The company is working on therapeutics and vaccines for infectious, autoimmune, immuno-oncology and cardiovascular diseases.

Moderna has a number of strategic partnerships with industry-leading names, such as Vertex Pharmaceuticals (VRTX), AstraZeneca (AZN) and Merck & Co (MRK). In 2020, it also worked with Lonza Group (LONN) and Catalent (CTLT) to manufacture its Covid-19 vaccine candidate mRNA-1273. At the end of 2020, the company had 12 programmes in clinical trials and a total of 23 development candidates.

Moderna shares are listed on the Nasdaq Stock Market under the ticker symbol MRNA. The company is a constituent of the NASDAQ-100 Index.

Stay up-to-date with the latest market news and watch the Moderna share price live at Capital.com.

The company was founded in 2010 as Moderna Therapeutics, with the goal of commercialising the research of stem-cell biologist Derrick Rossi. Apart from Rossi, Moderna’s co-founders were Noubar Afeyan, Robert Langer and Kenneth Chien. In August 2018, the company’s name was changed to Moderna.

In November 2020, Moderna’s Covid-19 vaccine candidate, mRNA-1273, showed preliminary evidence of 94.1 per cent efficacy in preventing the disease in a Phase 3 trial. The results led to its submission for emergency use authorisation in the US, Canada and Europe.

In late November, the EU made a deal with Moderna for up to 160 million doses of its vaccine. In December, the US government exercised its option to buy an additional 100 million doses of Moderna’s mRNA-1273, bringing the confirmed order commitment to 200 million doses.

With Capital.com’s Moderna share price chart, you can not only quickly view the current MRNA stock quote, but also trace the company’s share value in historic terms.

Moderna’s long-awaited initial public offering (IPO) happened in December 2018, with the firm selling 26.3 million shares priced at $23 each. At the time, it was the biggest biotech IPO ever. Moderna raised over $600m, valuing the company at $7.5bn (£5.6bn, €6.2bn).

In 2020, MRNA stock has been one of the US market’s best performers. This was due to rising investor enthusiasm over the company’s promising Covid-19 vaccine candidate. After opening the year at $19.57, the MRNA share price was on a hike, peaking at $94.85 in mid July. Within a month, it had dropped to $54.23, but then the stock gained another upside momentum, with its price surging past $100 on November 16. On December 8, the stock closed the trading day at $169.86, representing a year-to-date gain of nearly 770 per cent.

You can go long or short on the company’s shares and trace all the latest ups and downs of the Moderna Inc. stock price using Capital.com’s proprietary trading platform.

Industry:

Biotechnology & Medical Research (NEC)

200 Technology Sq
CAMBRIDGE
MASSACHUSETTS 02139-3578
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024